Sodium valproate acutely inhibits lamotrigine metabolism.
about
New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivityExtended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulationsIn vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)Lamotrigine-associated rash: risk/benefit considerations in adults and children.Lamotrigine.Is valproate pharmacotherapy associated with polycystic ovaries?Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients.Lamotrigine-induced rash: Can we stop worrying?Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies.Antiepileptic drug interactions.The importance of drug interactions in epilepsy therapy.Inhibition of phenobarbitone N-glucosidation by valproateProperties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies.New generation anticonvulsants for the treatment of epilepsy in children.Lamotrigine update and its use in mood disorders.Children versus adults: pharmacokinetic and adverse-effect differences.Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine serviceClinically relevant drug interactions with antiepileptic drugsInteractions between antiepileptic and antipsychotic drugs.Safety and tolerability of mood-stabilising anticonvulsants in the elderly.Antecedent Drug Exposure Aetiology and Management Protocols in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis, A Hospital Based Prospective StudyPharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders.Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions.Once-daily lamotrigine extended release for epilepsy management.Treatment of epilepsies associated with typical absences.Specific safety and tolerability considerations in the use of anticonvulsant medications in children.Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.Medication overuse and chronic migraine: a critical review according to clinical pharmacology.A pharmacological overview of lamotrigine for the treatment of epilepsy.Lamotrigine: an antiepileptic agent for the treatment of partial seizures.Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs.Lamotrigine: pharmacokinetics.A new generation of anticonvulsants for the treatment of epilepsy in children.Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transportersEffects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics.Interstitial pneumonitis during lamotrigine therapy.Expert Opinion on the Management of Lennox-Gastaut Syndrome: Treatment Algorithms and Practical Considerations.Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation.The effect of raltegravir on the glucuronidation of lamotrigine.
P2860
Q26800976-FA63941A-2C85-445F-9F48-AF80F646B8C2Q27027410-44221DF9-4A73-4BC2-AF9F-9107470D5C69Q28365901-1B8FBF17-43F7-4F9E-BA83-34DD3BCF7233Q33685953-2A422CFD-B2FC-4901-BE9B-FDBFB892F4EDQ33756771-D3FF9F7A-F293-424B-AD33-50050E34C10EQ33779880-99C51320-E1D0-4F44-98F4-79BE97744957Q33868103-96E62A06-0C91-43BE-B96D-6ED4D1E52626Q33948129-E7EDE329-35A2-430D-B5F2-49F4B94D428AQ34059330-4CA27974-1EB4-4A94-9A7F-E6D302457D69Q34090583-0865954D-6112-4D84-A84A-6CE7E41B6CB2Q34123652-65328364-72DE-4818-8E20-3C83CFF7D17DQ34346592-66ED6C63-D97D-4F66-AA45-0E6944F2665DQ34469479-84E9926B-45AB-4C3D-8684-916CFCD15DC2Q34504288-AEEA97E9-84AB-455B-88A4-3DB9E90AA9F2Q34615607-EA9A19A5-8F43-4518-9973-E94E7186EB30Q34680689-7D9B626B-850F-4B78-A6F6-94449CE3E562Q35802744-C1552F40-2C38-4679-B9E2-3289525EABCFQ35827491-2FE18068-EF62-4929-A07D-B827A673E604Q36384715-3158B828-4D97-4B16-B0AC-8163755C544AQ36446899-052632CB-4350-4A11-B810-F6DA2B3C765AQ36541832-981B94EF-7558-443B-8665-2E629637EF51Q36627204-9284E5FA-0426-4C65-BD18-E881ABDC7FA3Q36673011-9BD60C9D-D20B-4CAF-8485-C48201D9C64BQ37313452-2B479309-8C25-4555-B2FF-FBC2DEA0F0D6Q37390706-B7456496-AC80-4C36-B3C7-CA689C667C86Q37610185-6318319F-7D9E-44BB-B9FC-B6A3A0CA2BCCQ38026034-4EC2CB1A-CC39-4C55-923F-DE39B0BC2E2EQ38115721-994FAD07-B01E-463A-8024-0ED559014F17Q38509398-55E4D0A0-FDAE-412E-B3B8-07E645F6B97BQ39002973-BBA0BD9E-BBB1-40CB-8945-E24F13567629Q40529594-909A0DF1-3AC7-4B2C-8627-078925B4CC22Q41417980-B02C517F-0A84-4BA6-8121-E7BC594C06EDQ41681413-2E901F36-C5C9-442C-AE37-6470958DC549Q42136947-B19A6485-BC0B-4B78-8202-E4169AC4C948Q42282801-283DD8D4-E4F9-41B9-9CAC-DC108200B27AQ42633478-0477C0D0-FB50-4FB8-B03F-E3DC3511EDF8Q42707559-2B3EE4BD-A3F8-419F-BF76-5071118A2521Q43004735-842EE8DC-747D-4D8A-B5D1-02F26B8885E8Q43190362-8DB03D98-BD36-48D7-BC22-85DC34ADBD29Q43283574-FF9460CA-9EDC-4C8A-B2C0-408AEB595476
P2860
Sodium valproate acutely inhibits lamotrigine metabolism.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Sodium valproate acutely inhibits lamotrigine metabolism.
@en
Sodium valproate acutely inhibits lamotrigine metabolism.
@nl
type
label
Sodium valproate acutely inhibits lamotrigine metabolism.
@en
Sodium valproate acutely inhibits lamotrigine metabolism.
@nl
prefLabel
Sodium valproate acutely inhibits lamotrigine metabolism.
@en
Sodium valproate acutely inhibits lamotrigine metabolism.
@nl
P2093
P2860
P1476
Sodium valproate acutely inhibits lamotrigine metabolism.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1992.TB04079.X
P407
P577
1992-05-01T00:00:00Z